Cargando…

Reducing Episodic Cluster Headaches: Focus on Galcanezumab

The involvement of calcitonin gene-related peptide in migraine and cluster headache has led to the recent development of new therapies. Galcanezumab, a novel monoclonal antibody targeting the calcitonin gene-related peptide, is approved for the migraine prevention and has recently been tested for th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pellesi, Lanfranco, De Icco, Roberto, Al-Karagholi, Mohammad Al-Mahdi, Ashina, Messoud
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342329/ https://www.ncbi.nlm.nih.gov/pubmed/32753938 http://dx.doi.org/10.2147/JPR.S222604

Ejemplares similares

Effect of Vasoactive Intestinal Polypeptide on Development of Migraine Headaches: A Randomized Clinical Trial
por: Pellesi, Lanfranco, et al.
Publicado: (2021)

Debate: Are cluster headache and migraine distinct headache disorders?
por: Al-Karagholi, Mohammad Al-Mahdi, et al.
Publicado: (2022)

Plasma Levels of CGRP During a 2-h Infusion of VIP in Healthy Volunteers and Patients With Migraine: An Exploratory Study
por: Pellesi, Lanfranco, et al.
Publicado: (2022)

The role of high‐conductance calcium‐activated potassium channel in headache and migraine pathophysiology
por: Al‐Karagholi, Mohammad Al‐Mahdi, et al.
Publicado: (2022)

Migraine and cluster headache – the common link
por: Vollesen, Anne Luise, et al.
Publicado: (2018)

Glibenclamide Posttreatment Does Not Inhibit Levcromakalim Induced Headache in Healthy Participants: A Randomized Clinical Trial
por: Kokoti, Lili, et al.
Publicado: (2023)

The Effect of K(ATP) Channel Blocker Glibenclamide on CGRP-Induced Headache and Hemodynamic in Healthy Volunteers
por: Coskun, Hande, et al.
Publicado: (2021)

Plasma levels of VIP are not elevated during PACAP- and VIP-induced cluster headache attacks: an exploratory study
por: Deligianni, Christina, et al.
Publicado: (2023)

Investigation of cortical thickness and volume during spontaneous attacks of migraine without aura: a 3-Tesla MRI study
por: Amin, Faisal Mohammad, et al.
Publicado: (2021)

Involvement of adenosine signaling pathway in migraine pathophysiology: a systematic review of preclinical studies
por: Thuraiaiyah, Janu, et al.
Publicado: (2022)

Correction: Investigation of cortical thickness and volume during spontaneous attacks of migraine without aura: a 3-Tesla MRI study
por: Amin, Faisal Mohammad, et al.
Publicado: (2023)

Investigation of sumatriptan and ketorolac trometamol in the human experimental model of headache
por: Ghanizada, Hashmat, et al.
Publicado: (2020)

Preventive therapy with galcanezumab for two consecutive cluster bouts in patients with episodic cluster headache: an observational multicenter study
por: Hong, Yooha, et al.
Publicado: (2023)

Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment
por: Láinez, Miguel J. A., et al.
Publicado: (2021)

The K(ATP) channel in migraine pathophysiology: a novel therapeutic target for migraine
por: Al-Karagholi, Mohammad Al-Mahdi, et al.
Publicado: (2017)

Cluster headache – The worst possible pain on YouTube
por: Chaudhry, Basit Ali, et al.
Publicado: (2022)

Chronic headache and nitric oxide inhibitors
por: Ashina, Messoud, et al.
Publicado: (2001)

Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine
por: Ashina, Messoud, et al.
Publicado: (2021)

Real-world experience with 240 mg of galcanezumab for the preventive treatment of cluster headache
por: Mo, Heejung, et al.
Publicado: (2022)

Safety and Risk of Medication Overuse Headache in Lasmiditan and Second-Generation Gepants: A Rapid Review
por: Lo Castro, Flavia, et al.
Publicado: (2021)

PACAP38 in human models of primary headaches
por: Ashina, Håkan, et al.
Publicado: (2017)

Calcitonin Gene-Related Peptide in Tension-Type Headache
por: Ashina, Messoud
Publicado: (2001)

Triptans and CGRP blockade – impact on the cranial vasculature
por: Benemei, Silvia, et al.
Publicado: (2017)

Acute and preventive pharmacological treatment of post-traumatic headache: a systematic review
por: Larsen, Eigil Lindekilde, et al.
Publicado: (2019)

Fremanezumab and Non-High-Dose Galcanezumab for Comorbid Cluster Headache in Patients with Migraine: Three Cases
por: Kashiwagi, Kenta, et al.
Publicado: (2023)

Second messenger signalling bypasses CGRP receptor blockade to provoke migraine attacks in humans
por: Do, Thien Phu, et al.
Publicado: (2023)

Treatment Outcomes in Patients Treated With Galcanezumab vs Placebo: Post Hoc Analyses From a Phase 3 Randomized Study in Patients With Episodic Cluster Headache
por: Kudrow, David, et al.
Publicado: (2020)

Pituitary adenylate-cyclase-activating polypeptide (PACAP): another novel target for treatment of primary headaches?
por: Ashina, Messoud, et al.
Publicado: (2018)

Involvement of Potassium Channel Signalling in Migraine Pathophysiology
por: Al-Karagholi, Mohammad Al-Mahdi
Publicado: (2023)

Galcanezumab effects on incidence of headache after occurrence of triggers, premonitory symptoms, and aura in responders, non-responders, super-responders, and super non-responders
por: Ashina, Sait, et al.
Publicado: (2023)

Impact of Galcanezumab on Total Pain Burden: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Patients with Episodic Cluster Headache
por: Andrews, J Scott, et al.
Publicado: (2021)

Early Onset and Maintenance Effect of Galcanezumab in Japanese Patients with Episodic Migraine
por: Igarashi, Hisaka, et al.
Publicado: (2021)

Phase 1 study to access safety, tolerability, pharmacokinetics, and pharmacodynamics of kynurenine in healthy volunteers
por: Al‐Karagholi, Mohammad Al‐Mahdi, et al.
Publicado: (2021)

Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials
por: Yang, Yanbo, et al.
Publicado: (2020)

Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-controlled PREMIUM trial
por: Diener, Hans-Christoph, et al.
Publicado: (2019)

Galcanezumab for migraine
Publicado: (2020)

Interrelations between migraine-like headache and persistent post-traumatic headache attributed to mild traumatic brain injury: a prospective diary study
por: Ashina, Håkan, et al.
Publicado: (2020)

Migraine aura‐like episodes following sclerotherapy for varicose veins of the lower extremities—A systematic review
por: Bahtiri, Lionesa, et al.
Publicado: (2023)

Challenges and complexities in designing cluster headache prevention clinical trials: A narrative review
por: Dodick, David W., et al.
Publicado: (2022)

Response to Misused and Misleading: 100% Response Rate to Galcanezumab in Patients With Episodic Migraine
por: Rosen, Noah, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gp5s4attgq4q78qg80c5rmnf4d